{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:42:25Z","timestamp":1787020945537,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100012526","name":"Sundhedsvidenskabelige Fakultet, Aarhus Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012526","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Tonix Pharmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"DOI":"10.1186\/s13550-025-01329-0","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T11:22:47Z","timestamp":1763464967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["First-in-human intranasal [13N]oxytocin PET: evaluation of feasibility, biodistribution, and radiation dosimetry"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8790-7574","authenticated-orcid":false,"given":"Michael","family":"Winterdahl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik Nguyen","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren B.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 Henrique","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkel Holm","family":"Vendelbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steen","family":"Jakobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Yeomans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"issue":"1","key":"1329_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-023-00540-3","volume":"23","author":"I Alberts","year":"2023","unstructured":"Alberts I, Sari H, Mingels C, Afshar-Oromieh A, Pyka T, Shi K, et al. Long-axial field-of-view PET\/CT: perspectives and review of a revolutionary development in nuclear medicine based on clinical experience in over 7000 patients. Cancer Imaging. 2023;23(1):28. https:\/\/doi.org\/10.1186\/s40644-023-00540-3.","journal-title":"Cancer Imaging"},{"issue":"3","key":"1329_CR2","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s11930-020-00274-4","volume":"12","author":"JC Alley","year":"2020","unstructured":"Alley JC, Diamond LM. Oxytocin and human sexuality: recent developments. Curr Sex Health Rep. 2020;12(3):182\u20135. https:\/\/doi.org\/10.1007\/s11930-020-00274-4.","journal-title":"Curr Sex Health Rep"},{"issue":"7","key":"1329_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13071088","volume":"13","author":"VN Bharadwaj","year":"2021","unstructured":"Bharadwaj VN, Tzabazis AZ, Klukinov M, Manering NA, Yeomans DC. Intranasal administration for pain: oxytocin and other polypeptides. Pharmaceutics. 2021;13(7):1088. https:\/\/doi.org\/10.3390\/pharmaceutics13071088.","journal-title":"Pharmaceutics"},{"issue":"3","key":"1329_CR4","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/0968-0004(91)90044-v","volume":"16","author":"AF Bradbury","year":"1991","unstructured":"Bradbury AF, Smyth DG. Peptide amidation. Trends Biochem Sci. 1991;16(3):112\u20135. https:\/\/doi.org\/10.1016\/0968-0004(91)90044-v.","journal-title":"Trends Biochem Sci"},{"issue":"10","key":"1329_CR5","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1007\/s11095-012-0915-1","volume":"30","author":"CD Chapman","year":"2013","unstructured":"Chapman CD, Frey WH, Craft S, Danielyan L, Hallschmid M, Schi\u00f6th HB, et al. Intranasal treatment of central nervous system dysfunction in humans. Pharm Res. 2013;30(10):2475\u201384. https:\/\/doi.org\/10.1007\/s11095-012-0915-1.","journal-title":"Pharm Res"},{"issue":"4","key":"1329_CR6","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1002\/jps.21924","volume":"99","author":"SV Dhuria","year":"2010","unstructured":"Dhuria SV, Hanson LR, Frey WH. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci. 2010;99(4):1654\u201373. https:\/\/doi.org\/10.1002\/jps.21924.","journal-title":"J Pharm Sci"},{"issue":"1","key":"1329_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-64528-w","volume":"10","author":"B Garforth","year":"2020","unstructured":"Garforth B, Degnbol H, Terris ET, Zak PJ, Winterdahl M. Elevated plasma oxytocin levels and higher satisfaction with life in young oral contraceptive users. Sci Rep. 2020;10(1):8208. https:\/\/doi.org\/10.1038\/s41598-020-64528-w.","journal-title":"Sci Rep"},{"issue":"5","key":"1329_CR8","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1118\/1.4945416","volume":"43","author":"AM Grant","year":"2016","unstructured":"Grant AM, Deller TW, Khalighi MM, Maramraju SH, Delso G, Levin CS. NEMA NU 2\u20132012 performance studies for the SiPM-based ToF-PET component of the GE SIGNA PET\/MR system. Med Phys. 2016;43(5):2334\u201343. https:\/\/doi.org\/10.1118\/1.4945416.","journal-title":"Med Phys"},{"issue":"3","key":"1329_CR9","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.yhbeh.2012.01.002","volume":"61","author":"AJ Graustella","year":"2012","unstructured":"Graustella AJ, MacLeod C. A critical review of the influence of oxytocin nasal spray on social cognition in humans: evidence and future directions. Horm Behav. 2012;61(3):410\u20138. https:\/\/doi.org\/10.1016\/j.yhbeh.2012.01.002.","journal-title":"Horm Behav"},{"issue":"4","key":"1329_CR10","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/hbm.10123","volume":"19","author":"A Hammers","year":"2003","unstructured":"Hammers A, Allom R, Koepp MJ, Free SL, Myers R, Lemieux L, et al. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp. 2003;19(4):224\u201347. https:\/\/doi.org\/10.1002\/hbm.10123.","journal-title":"Hum Brain Mapp"},{"key":"1329_CR11","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.neubiorev.2020.12.028","volume":"122","author":"Y Huang","year":"2021","unstructured":"Huang Y, Huang X, Ebstein RP, Yu R. Intranasal oxytocin in the treatment of autism spectrum disorders: a multilevel meta-analysis. Neurosci Biobehav Rev. 2021;122:18\u201327. https:\/\/doi.org\/10.1016\/j.neubiorev.2020.12.028.","journal-title":"Neurosci Biobehav Rev"},{"issue":"1","key":"1329_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0928-0987(00)00087-7","volume":"11","author":"L Illum","year":"2000","unstructured":"Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci. 2000;11(1):1\u201318. https:\/\/doi.org\/10.1016\/S0928-0987(00)00087-7.","journal-title":"Eur J Pharm Sci"},{"issue":"7","key":"1329_CR13","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.2967\/jnumed.122.264225","volume":"64","author":"AL Kesner","year":"2023","unstructured":"Kesner AL, Carter LM, Ramos JCO, Lafontaine D, Olguin EA, Brown JL, et al. MIRD pamphlet no. 28, Part 1: MIRDcalc-a software tool for medical internal radiation dosimetry. J Nucl Med. 2023;64(7):1117\u201324. https:\/\/doi.org\/10.2967\/jnumed.122.264225.","journal-title":"J Nucl Med"},{"issue":"1","key":"1329_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15942-1","volume":"11","author":"MR Lee","year":"2020","unstructured":"Lee MR, Shnitko TA, Blue SW, Kaucher AV, Winchell AJ, Erikson DW, et al. Labeled oxytocin administered via the intranasal route reaches the brain in rhesus macaques. Nat Commun. 2020;11(1):2783. https:\/\/doi.org\/10.1038\/s41467-020-15942-1.","journal-title":"Nat Commun"},{"issue":"3","key":"1329_CR15","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.biopsych.2015.05.003","volume":"79","author":"G Leng","year":"2016","unstructured":"Leng G, Ludwig M. Intranasal oxytocin: myths and delusions. Biol Psychiatry. 2016;79(3):243\u201350. https:\/\/doi.org\/10.1016\/j.biopsych.2015.05.003.","journal-title":"Biol Psychiatry"},{"issue":"7","key":"1329_CR16","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","volume":"64","author":"JJ Lochhead","year":"2012","unstructured":"Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev. 2012;64(7):614\u201328. https:\/\/doi.org\/10.1016\/j.addr.2011.11.002.","journal-title":"Adv Drug Deliv Rev"},{"key":"1329_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2022.102239","volume":"211","author":"D Martins","year":"2022","unstructured":"Martins D, Brodmann K, Veronese M, Dipasquale O, Mazibuko N, Schuschnig U, et al. \u201cLess is more\u201d: A dose-response account of intranasal oxytocin pharmacodynamics in the human brain. Prog Neurobiol. 2022;211:102239. https:\/\/doi.org\/10.1016\/j.pneurobio.2022.102239.","journal-title":"Prog Neurobiol"},{"issue":"6","key":"1329_CR18","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3109\/10611869808997870","volume":"5","author":"S Mathison","year":"1998","unstructured":"Mathison S, Nagilla R, Kompella UB. Nasal route for direct delivery of solutes to the central nervous system: fact or fiction? J Drug Target. 1998;5(6):415\u201341. https:\/\/doi.org\/10.3109\/10611869808997870.","journal-title":"J Drug Target"},{"key":"1329_CR19","doi-asserted-by":"publisher","unstructured":"McEwen, BB. Brain-fluid barriers: Relevance for theoretical controversies regarding vasopressin and oxytocin memory research. Advances in Pharmacology .\u00a02004;50:\u00a0531\u2013592, 655\u2013708. https:\/\/doi.org\/10.1016\/S1054-3589(04)50014-5","DOI":"10.1016\/S1054-3589(04)50014-5"},{"issue":"1","key":"1329_CR20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/mp.2015.166","volume":"21","author":"DS Quintana","year":"2016","unstructured":"Quintana DS, Guastella AJ, Westlye LT, Andreassen OA. The promise and pitfalls of intranasally administering psychopharmacological agents for the treatment of psychiatric disorders. Mol Psychiatry. 2016;21(1):29\u201338. https:\/\/doi.org\/10.1038\/mp.2015.166.","journal-title":"Mol Psychiatry"},{"issue":"1","key":"1329_CR21","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41380-020-00864-7","volume":"26","author":"DS Quintana","year":"2021","unstructured":"Quintana DS, Lischke A, Grace S, Scheele D, Ma Y, Becker B. Advances in the field of intranasal oxytocin research: lessons learned and future directions for clinical research. Mol Psychiatry. 2021;26(1):80\u201391. https:\/\/doi.org\/10.1038\/s41380-020-00864-7.","journal-title":"Mol Psychiatry"},{"issue":"1","key":"1329_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08503-8","volume":"10","author":"DS Quintana","year":"2019","unstructured":"Quintana DS, Rokicki J, van der Meer D, Aln\u00e6s D, Kaufmann T, C\u00f3rdova-Palomera A, et al. Oxytocin pathway gene networks in the human brain. Nat Commun. 2019;10(1):668. https:\/\/doi.org\/10.1038\/s41467-019-08503-8.","journal-title":"Nat Commun"},{"issue":"7","key":"1329_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2015.93","volume":"5","author":"DS Quintana","year":"2015","unstructured":"Quintana DS, Westlye LT, Rustan \u00d8G, Tesli N, Poppy CL, Smevik H, et al. Low-dose oxytocin delivered intranasally with breath powered device affects social-cognitive behavior: a randomized four-way crossover trial with nasal cavity dimension assessment. Transl Psychiatry. 2015;5(7):e602\u2013e602. https:\/\/doi.org\/10.1038\/tp.2015.93.","journal-title":"Transl Psychiatry"},{"issue":"4","key":"1329_CR24","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1159\/000507761","volume":"111","author":"A Sundl\u00f6v","year":"2021","unstructured":"Sundl\u00f6v A, Sj\u00f6green-Gleisner K, Tennvall J, Dahl L, Svensson J, \u00c5kesson A, et al. Pituitary function after high-dose 177Lu-DOTATATE therapy and long-term follow-up. Neuroendocrinology. 2021;111(4):344\u201353. https:\/\/doi.org\/10.1159\/000507761.","journal-title":"Neuroendocrinology"},{"key":"1329_CR25","doi-asserted-by":"publisher","unstructured":"The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103. Annals of the ICRP.\u00a02007;37(2\u20134), 1\u2013332. https:\/\/doi.org\/10.1016\/j.icrp.2007.10.003\u00a0","DOI":"10.1016\/j.icrp.2007.10.003"},{"issue":"Suppl 2","key":"1329_CR26","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/head.13082","volume":"57","author":"A Tzabazis","year":"2017","unstructured":"Tzabazis A, Kori S, Mechanic J, Miller J, Pascual C, Manering N, et al. Oxytocin and migraine headache. Headache. 2017;57(Suppl 2):64\u201375. https:\/\/doi.org\/10.1111\/head.13082.","journal-title":"Headache"},{"issue":"4","key":"1329_CR27","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s40336-023-00547-7","volume":"11","author":"L Urso","year":"2023","unstructured":"Urso L, Frantellizzi V, De Vincentis G, Schillaci O, Filippi L, Evangelista L. Clinical applications of long axial field-of-view PET\/CT scanners in oncology. Clin Transl Imaging. 2023;11(4):365\u201380. https:\/\/doi.org\/10.1007\/s40336-023-00547-7.","journal-title":"Clin Transl Imaging"},{"issue":"3","key":"1329_CR28","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1159\/000299248","volume":"16","author":"L Vankrieken","year":"1983","unstructured":"Vankrieken L, Godart A, Thomas K. Oxytocin determination by radioimmunoassay. Gynecol Obstet Invest. 1983;16(3):180\u20135. https:\/\/doi.org\/10.1159\/000299248.","journal-title":"Gynecol Obstet Invest"},{"key":"1329_CR29","doi-asserted-by":"publisher","unstructured":"Werry, EL, Kassiou, M. Measuring Affinity of Ligands to the Oxytocin Receptor Using Radioligand Binding. Methods in Molecular Biology .\u00a02022;2384:\u00a0231\u2013245. https:\/\/doi.org\/10.1007\/978-1-0716-1759-5_14","DOI":"10.1007\/978-1-0716-1759-5_14"},{"issue":"1","key":"1329_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-021-01511-7","volume":"11","author":"DC Yeomans","year":"2021","unstructured":"Yeomans DC, Hanson LR, Carson DS, Tunstall BJ, Lee MR, Tzabazis AZ, et al. Nasal oxytocin for the treatment of psychiatric disorders and pain: Achieving meaningful brain concentrations. Transl Psychiatry. 2021;11(1):1\u201310. https:\/\/doi.org\/10.1038\/s41398-021-01511-7.","journal-title":"Transl Psychiatry"},{"issue":"1","key":"1329_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-023-01173-6","volume":"13","author":"S Zhang","year":"2023","unstructured":"Zhang S, Zhang Y-D, Shi D-D, Wang Z. Therapeutic uses of oxytocin in stress-related neuropsychiatric disorders. Cell Biosci. 2023;13(1):216. https:\/\/doi.org\/10.1186\/s13578-023-01173-6.","journal-title":"Cell Biosci"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-025-01329-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-025-01329-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-025-01329-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:04:29Z","timestamp":1763510669000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmires.springeropen.com\/articles\/10.1186\/s13550-025-01329-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1329"],"URL":"https:\/\/doi.org\/10.1186\/s13550-025-01329-0","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"19 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the Central Denmark Region (case number 77797). All participants provided written informed consent prior to participation. All procedures were conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"David Yeomans is a consultant for Tonix Pharmaceuticals. The remaining authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"137"}}